Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4631571 | 0.79 | ALDH1A1 (0.35) | ALDH1A1FFAR3TDP1TSHRMAPK1 | |
| Zinc Ion SCHEMBL15136365 | 0.78 | FFAR3 (0.32) | ALDH1A1FFAR3TSHRMAPK1 | |
| SCHEMBL14605066 | 0.78 | FFAR3 (0.36) | ALDH1A1FFAR3TSHRMAPK1CA1 | |
| SCHEMBL4184059 | 0.74 | TSHR (0.36) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL4557462 | 0.74 | TSHR (0.32) | ALDH1A1TDP1TSHRMAPK1 | |
| SCHEMBL11301434 | 0.74 | ALDH1A1 (0.32) | ALDH1A1TSHRMAPK1 | |
| Carbamic Acid SCHEMBL1300288 | 0.72 | — | — | |
| SCHEMBL3257895 | 0.72 | FFAR3 (0.32) | ALDH1A1FFAR3TSHRMAPK1 | |
| SCHEMBL7282131 | 0.70 | TSHR (0.33) | TSHRMAPK1 | |
| SCHEMBL11301441 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6399051-B2 | KERATIN REDUCING AGENT | WELLA AKTIENGESELLSCHAFT (DE) | 2002-06-04 | — | — | US | claimed |
| EP-0969792-B1 | METHOD AND AGENTS FOR PERMANENTLY STYLING HAIR, WITH A BASE CONSISTING OF N,N-DISUBSTITUTED MERCAPTOACETAMIDES, AND METHOD FOR PRODUCING SAID MERCAPTOACETAMIDES | WELLA AG (DE) | 2003-11-12 | — | — | EP | disclosed |
| US-6399051-B2 | KERATIN REDUCING AGENT | WELLA AKTIENGESELLSCHAFT (DE) | 2002-06-04 | — | — | US | disclosed |
| US-20010056208-A1 | METHOD AND AGENTS FOR PERMANENTLY STYLING HAIR, WITH A BASE CONSISTING OF N,N-DISUBSTITUTED MERCAPTOACETAMIDES, AND METHOD FOR PRODUCING SAID MERCAPTOACETAMIDES | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2001-12-27 | — | — | US | disclosed |
| EP-0969792-A2 | METHOD AND AGENTS FOR PERMANENTLY STYLING HAIR, WITH A BASE CONSISTING OF N,N-DISUBSTITUTED MERCAPTOACETAMIDES, AND METHOD FOR PRODUCING SAID MERCAPTOACETAMIDES | Wella Aktiengesellschaft (DE) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999007330-A2 | METHOD AND AGENTS FOR PERMANENTLY STYLING HAIR, WITH A BASE CONSISTING OF N,N-DISUBSTITUTED MERCAPTOACETAMIDES, AND METHOD FOR PRODUCING SAID MERCAPTOACETAMIDES | WELLA AKTIENGESELLSCHAFT (DE) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056208-A1 | METHOD AND AGENTS FOR PERMANENTLY STYLING HAIR, WITH A BASE CONSISTING OF N,N-DISUBSTITUTED MERCAPTOACETAMIDES, AND METHOD FOR PRODUCING SAID MERCAPTOACETAMIDES | KRT18, BHMT2, NACA | ALDH1A1 356/4885FFAR3 1368/4885TDP1 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.